[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Repaglinide.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Repaglinide.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Repaglinide.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Sulfamethoxazole.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfapyridine.]
[M04AB02, sulfinpyrazone, Repaglinide may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Sulfisoxazole is combined with Repaglinide.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Glymidine.]
[L02BA01, tamoxifen, Tamoxifen may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may increase the hypoglycemic activities of Repaglinide.]
[N05AE05, lurasidone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lurasidone.]
[N04BC07, apomorphine, The metabolism of Repaglinide can be decreased when combined with Apomorphine.]
[R03DA04, theophylline, The metabolism of Repaglinide can be decreased when combined with Theophylline.]
[B01AC05, ticlopidine, The metabolism of Repaglinide can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Repaglinide.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Tolbutamide.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypoglycemic activities of Repaglinide.]
[L01XF01, tretinoin, The metabolism of Repaglinide can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Repaglinide.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Trichlormethiazide.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Repaglinide.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Repaglinide.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Repaglinide.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Repaglinide.]
[A03AA05, trimebutine, The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Repaglinide.]
[N03AC02, trimethadione, The metabolism of Repaglinide can be decreased when combined with Trimethadione.]
[J01EA01, trimethoprim, The serum concentration of Repaglinide can be increased when it is combined with Trimethoprim.]
[N06AA06, trimipramine, Trimipramine may decrease the hypoglycemic activities of Repaglinide.]
[J01FA08, troleandomycin, The serum concentration of Repaglinide can be increased when it is combined with Troleandomycin.]
[L02BX03, abiraterone, The metabolism of Repaglinide can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Repaglinide can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Repaglinide can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Repaglinide can be decreased when combined with Rilpivirine.]
[C08DA01, verapamil, The metabolism of Repaglinide can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Repaglinide can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, Vinblastine may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[L01CA02, vincristine, Vincristine may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C03BA10, xipamide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Xipamide.]
[J05AF01, zidovudine, The metabolism of Repaglinide can be decreased when combined with Zidovudine.]
[J05AE02, indinavir, The metabolism of Repaglinide can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The therapeutic efficacy of Repaglinide can be increased when used in combination with Vemurafenib.]
[L01ED01, crizotinib, The metabolism of Repaglinide can be decreased when combined with Crizotinib.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Drospirenone.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Repaglinide.]
[C07AB03, atenolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Atenolol.]
[J02AC03, voriconazole, The metabolism of Repaglinide can be decreased when combined with Voriconazole.]
[S01FA01, atropine, Atropine may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[L01EK01, axitinib, The excretion of Repaglinide can be decreased when combined with Axitinib.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Repaglinide.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Repaglinide.]
[M03BX01, baclofen, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Baclofen.]
[V03AX03, cobicistat, The metabolism of Repaglinide can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Repaglinide can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Repaglinide can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Repaglinide can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The serum concentration of Repaglinide can be increased when it is combined with Teriflunomide.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Repaglinide.]
[J05AE04, nelfinavir, The metabolism of Repaglinide can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Rasagiline may increase the hypoglycemic activities of Repaglinide.]
[C08CA13, lercanidipine, The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Repaglinide.]
[L01EX07, cabozantinib, The metabolism of Repaglinide can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Pasireotide.]
[G04BE03, sildenafil, The excretion of Repaglinide can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Repaglinide.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Repaglinide.]
[C04AX11, bencyclane, The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Repaglinide.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Alogliptin.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Bendroflumethiazide.]
[A10BK02, canagliflozin, Canagliflozin may increase the hypoglycemic activities of Repaglinide.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Gemifloxacin.]
[M04AB03, benzbromarone, Repaglinide may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Repaglinide can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Repaglinide.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin detemir.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Pramlintide.]
[J02AX04, caspofungin, The excretion of Repaglinide can be decreased when combined with Caspofungin.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[L04AA18, everolimus, The serum concentration of Repaglinide can be increased when it is combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Repaglinide can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Repaglinide can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Repaglinide.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Repaglinide.]
[C08EA02, bepridil, The risk or severity of hypoglycemia can be increased when Bepridil is combined with Repaglinide.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Repaglinide.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Lixisenatide.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Repaglinide.]
[G03AC08, etonogestrel, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Repaglinide.]
[C07AB04, acebutolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Acebutolol.]
[A16AA07, metreleptin, The metabolism of Repaglinide can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Repaglinide can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Repaglinide.]
[S01ED02, betaxolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Betaxolol.]
[C10AB02, bezafibrate, The metabolism of Repaglinide can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Repaglinide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Ceritinib.]
[L01EM01, idelalisib, The excretion of Repaglinide can be decreased when combined with Idelalisib.]
[A10BK03, empagliflozin, Empagliflozin may increase the hypoglycemic activities of Repaglinide.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Repaglinide.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Dulaglutide.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Repaglinide.]
[L04AC10, secukinumab, The metabolism of Repaglinide can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[J05AP07, daclatasvir, The excretion of Repaglinide can be decreased when combined with Daclatasvir.]
[J05AP06, asunaprevir, The excretion of Repaglinide can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The excretion of Repaglinide can be decreased when combined with Eluxadoline.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Brexpiprazole.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Acarbose is combined with Repaglinide.]
[S01EC01, acetazolamide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin degludec.]
[A02BC03, lansoprazole, The metabolism of Repaglinide can be decreased when combined with Lansoprazole.]
[J02AC05, isavuconazole, The metabolism of Repaglinide can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Repaglinide.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Acetohexamide.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Repaglinide.]
[L01XX52, venetoclax, The metabolism of Repaglinide can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Bromocriptine.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Repaglinide.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Repaglinide.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Repaglinide.]
[C03CA02, bumetanide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Bumetanide.]
[C07AA19, bupranolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Repaglinide.]
[L02AE01, buserelin, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Buserelin.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Arsenic trioxide.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sparfloxacin.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Repaglinide.]
[L01EF02, ribociclib, The metabolism of Repaglinide can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Repaglinide.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Repaglinide.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Repaglinide.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Benfluorex.]
[J01XX08, linezolid, Linezolid may increase the hypoglycemic activities of Repaglinide.]
[J05AE09, tipranavir, The metabolism of Repaglinide can be decreased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Repaglinide can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Repaglinide can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Repaglinide.]
[N04BD03, safinamide, Safinamide may increase the hypoglycemic activities of Repaglinide.]
[J01MA23, delafloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Delafloxacin.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Repaglinide.]
[L01XH01, vorinostat, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Repaglinide can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Bopindolol.]
[V03AB23, acetylcysteine, The excretion of Repaglinide can be decreased when combined with Acetylcysteine.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Repaglinide.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Repaglinide.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Semaglutide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Ertugliflozin.]
[L02BB05, apalutamide, The metabolism of Repaglinide can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Repaglinide can be increased when combined with Carbamazepine.]
[C07AG02, carvedilol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Repaglinide can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Repaglinide can be increased when combined with Avatrombopag.]
[C07AB08, celiprolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Repaglinide.]
[L01XX62, ivosidenib, The metabolism of Repaglinide can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Repaglinide can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The serum concentration of Repaglinide can be increased when it is combined with Tecovirimat.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Carbutamide.]
[L04AA39, emapalumab, The metabolism of Repaglinide can be increased when combined with Emapalumab.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Repaglinide.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Repaglinide.]
[P02BX04, triclabendazole, The metabolism of Repaglinide can be decreased when combined with Triclabendazole.]
[J01FA09, clarithromycin, The serum concentration of Repaglinide can be increased when it is combined with Clarithromycin.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Repaglinide.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Repaglinide.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Repaglinide.]
[C09CA06, candesartan, The metabolism of Repaglinide can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Repaglinide can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Repaglinide.]
[L01EM03, alpelisib, The metabolism of Repaglinide can be decreased when combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[L02BB06, darolutamide, The excretion of Repaglinide can be decreased when combined with Darolutamide.]
[L01EX15, pexidartinib, The excretion of Repaglinide can be decreased when combined with Pexidartinib.]
[L01EJ02, fedratinib, The excretion of Repaglinide can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The serum concentration of Repaglinide can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Repaglinide.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin pork.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Repaglinide.]
[G03AC09, desogestrel, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Desogestrel.]
[N03AX25, cenobamate, The serum concentration of Repaglinide can be decreased when it is combined with Cenobamate.]
[L04AA53, teprotumumab, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Teprotumumab.]
[C10AX15, bempedoic acid, The excretion of Repaglinide can be decreased when combined with Bempedoic acid.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Gatifloxacin.]
[J05AE05, amprenavir, The metabolism of Repaglinide can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Repaglinide.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Repaglinide.]
[G03DB08, dienogest, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Repaglinide.]
[M01AH02, rofecoxib, The metabolism of Repaglinide can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Repaglinide can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Repaglinide.]
[C01BD07, dronedarone, The metabolism of Repaglinide can be decreased when combined with Dronedarone.]
[J01FA13, dirithromycin, The serum concentration of Repaglinide can be increased when it is combined with Dirithromycin.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Repaglinide.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Repaglinide.]
[L01EX22, selpercatinib, The serum concentration of Repaglinide can be increased when it is combined with Selpercatinib.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Repaglinide.]
[C08CA17, levamlodipine, The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Repaglinide.]
[J05AX29, fostemsavir, The excretion of Repaglinide can be decreased when combined with Fostemsavir.]
[L01FX15, belantamab mafodotin, Repaglinide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Repaglinide can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Repaglinide can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Repaglinide.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Chlorthalidone.]
[V04CK02, cholecystokinin, The excretion of Repaglinide can be decreased when combined with Cholecystokinin.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Repaglinide.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Repaglinide.]
[B06AC06, berotralstat, The metabolism of Repaglinide can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Repaglinide can be decreased when combined with Lonafarnib.]
[P03AX07, abametapir, The serum concentration of Repaglinide can be increased when it is combined with Abametapir.]
[J01MB07, flumequine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Repaglinide.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Repaglinide.]
[S01JA01, fluorescein, Fluorescein may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin human.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Repaglinide.]
[J01MB06, cinoxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Repaglinide can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Repaglinide.]
[H01AC07, somapacitan, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Repaglinide.]
[L04AA48, belumosudil, The excretion of Repaglinide can be decreased when combined with Belumosudil.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lonapegsomatropin.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Repaglinide.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Gliquidone.]
[J01FF01, clindamycin, The serum concentration of Repaglinide can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Repaglinide can be increased when combined with St. John's Wort.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Repaglinide.]
[B06AX04, mitapivat, The therapeutic efficacy of Repaglinide can be increased when used in combination with Mitapivat.]
[N06AA04, clomipramine, Clomipramine may decrease the hypoglycemic activities of Repaglinide.]
[C01EB24, mavacamten, The serum concentration of Repaglinide can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Clopamide.]
[A05BA08, glycyrrhizic acid, Repaglinide may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[H01CC04, linzagolix, The serum concentration of Repaglinide can be increased when it is combined with Linzagolix.]
[N05AH02, clozapine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Sotagliflozin.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Repaglinide.]
[H01AC08, somatrogon, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Somatrogon.]
[L04AC21, bimekizumab, The metabolism of Repaglinide can be increased when combined with Bimekizumab.]
[L04AA13, leflunomide, The serum concentration of Repaglinide can be increased when it is combined with Leflunomide.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Repaglinide.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin glargine.]
[J01FA15, telithromycin, The serum concentration of Repaglinide can be increased when it is combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Repaglinide.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Repaglinide.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Repaglinide.]
[J02AC02, itraconazole, The metabolism of Repaglinide can be decreased when combined with Itraconazole.]
[L01EA01, imatinib, Imatinib may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[J02AC04, posaconazole, The metabolism of Repaglinide can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Repaglinide.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Repaglinide.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Lomefloxacin.]
[R06AX13, loratadine, The metabolism of Repaglinide can be decreased when combined with Loratadine.]
[C08CA11, manidipine, The risk or severity of hypoglycemia can be increased when Manidipine is combined with Repaglinide.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Repaglinide.]
[C07AA14, mepindolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Repaglinide.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Repaglinide.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Cyclopenthiazide.]
[J01FA03, midecamycin, The serum concentration of Repaglinide can be increased when it is combined with Midecamycin.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Miglitol is combined with Repaglinide.]
[L01AA01, cyclophosphamide, The metabolism of Repaglinide can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the hypoglycemic activities of Repaglinide.]
[S01XA18, cyclosporine, The serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypoglycemic activities of Repaglinide.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Repaglinide can be decreased when combined with Conivaptan.]
[G03XA01, danazol, The metabolism of Repaglinide can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Repaglinide can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, Daunorubicin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C07AB12, nebivolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Repaglinide can be decreased when combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Repaglinide can be decreased when combined with Nilutamide.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Repaglinide.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Repaglinide.]
[N06AA01, desipramine, Desipramine may decrease the hypoglycemic activities of Repaglinide.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Repaglinide.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Repaglinide.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Repaglinide.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Repaglinide.]
[G04BD04, oxybutynin, The metabolism of Repaglinide can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Repaglinide can be increased when combined with Adalimumab.]
[N03AC01, paramethadione, The metabolism of Repaglinide can be decreased when combined with Paramethadione.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Repaglinide.]
[B01AC04, clopidogrel, The risk or severity of hypoglycemia can be increased when Clopidogrel is combined with Repaglinide.]
[V03AH01, diazoxide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Diazoxide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Repaglinide.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Repaglinide can be increased when used in combination with Phthalylsulfathiazole.]
[A03AX04, pinaverium, The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Repaglinide.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Pioglitazone.]
[L01DC04, ixabepilone, The serum concentration of Repaglinide can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Repaglinide.]
[C03CA03, piretanide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Piretanide.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C08CA03, isradipine, The metabolism of Repaglinide can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Repaglinide.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Repaglinide.]
[C01AA05, digoxin, Digoxin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C10AX09, ezetimibe, Repaglinide may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Repaglinide may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Repaglinide can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Repaglinide can be decreased when combined with Treprostinil.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Repaglinide.]
[C08DB01, diltiazem, The metabolism of Repaglinide can be decreased when combined with Diltiazem.]
[B01AC07, dipyridamole, Repaglinide may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Repaglinide.]
[A03FA02, cisapride, The metabolism of Repaglinide can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The serum concentration of Repaglinide can be increased when it is combined with Sirolimus.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Repaglinide.]
[P03AA04, disulfiram, Disulfiram may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[S02AA12, rifamycin SV, The metabolism of Repaglinide can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Repaglinide can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Risperidone.]
[J01MB01, rosoxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Repaglinide can be decreased when combined with Aprepitant.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Fosamprenavir.]
[S01BC05, ketorolac, The metabolism of Repaglinide can be decreased when combined with Ketorolac.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[R03AC12, salmeterol, The metabolism of Repaglinide can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Repaglinide.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Repaglinide.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Repaglinide.]
[L01DB01, doxorubicin, Repaglinide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Repaglinide.]
[C10AA01, simvastatin, Simvastatin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Repaglinide can be increased when used in combination with Succinylsulfathiazole.]
[N02CC01, sumatriptan, The therapeutic efficacy of Repaglinide can be increased when used in combination with Sumatriptan.]
[C07AB13, talinolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Repaglinide.]
[J01MA05, temafloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Repaglinide can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of hypoglycemia can be increased when Terodiline is combined with Repaglinide.]
[C07AA16, tertatolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Repaglinide.]
[N06AG03, toloxatone, Toloxatone may increase the hypoglycemic activities of Repaglinide.]
[C03CA04, torsemide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Torasemide.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Repaglinide.]
[L02AE04, triptorelin, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Triptorelin.]
[J01MA04, enoxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Enoxacin.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Repaglinide.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Repaglinide.]
[C08CA12, mepirodipine, The metabolism of Repaglinide can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Epinephrine.]
[N03AX15, zonisamide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Repaglinide.]
[N02CA02, ergotamine, The metabolism of Repaglinide can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The serum concentration of Repaglinide can be increased when it is combined with Erythromycin.]
[A02BC02, pantoprazole, The excretion of Repaglinide can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The excretion of Repaglinide can be decreased when combined with Conjugated estrogens.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Repaglinide.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Repaglinide.]
[C10AA04, fluvastatin, The metabolism of Repaglinide can be decreased when combined with Fluvastatin.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Repaglinide.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[N03AD01, ethosuximide, The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Repaglinide.]
[L04AD02, tacrolimus, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Tacrolimus.]
[J01MA08, fleroxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Fleroxacin.]
[R06AX11, astemizole, Astemizole may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[R06AX12, terfenadine, The metabolism of Repaglinide can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Repaglinide.]
[L02AE02, leuprolide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Repaglinide which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA01, levocarnitine, The excretion of Repaglinide can be decreased when combined with Levocarnitine.]
[C08CA02, felodipine, The metabolism of Repaglinide can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Repaglinide.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Repaglinide.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Repaglinide.]
[N07CA03, flunarizine, The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Repaglinide.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Repaglinide.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Repaglinide.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Repaglinide.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Repaglinide.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Repaglinide.]
[N06AB03, fluoxetine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Repaglinide.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Repaglinide.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Repaglinide.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Repaglinide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Repaglinide.]
[G01AX06, furazolidone, Furazolidone may increase the hypoglycemic activities of Repaglinide.]
[J05AE10, darunavir, The metabolism of Repaglinide can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, The metabolism of Repaglinide can be decreased when combined with Eszopiclone.]
[C08DA02, gallopamil, The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Repaglinide.]
[C10AB04, gemfibrozil, The serum concentration of Repaglinide can be increased when it is combined with Gemfibrozil.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Liraglutide.]
[N03AD03, methsuximide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Repaglinide.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Repaglinide.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Glipizide.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Repaglinide.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Repaglinide.]
[L02AE03, goserelin, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Repaglinide.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Repaglinide.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Repaglinide.]
[L02AE05, histrelin, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Quetiapine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin aspart.]
[L01CE02, irinotecan, The excretion of Repaglinide can be decreased when combined with Irinotecan.]
[C09CA01, losartan, Losartan may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Repaglinide.]
[C08CA10, nilvadipine, The metabolism of Repaglinide can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Repaglinide.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Repaglinide.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Repaglinide.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Repaglinide.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Repaglinide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydroflumethiazide.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Hydroxychloroquine.]
[J04AB04, rifabutin, The metabolism of Repaglinide can be increased when combined with Rifabutin.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Repaglinide.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Repaglinide.]
[L01AA06, ifosfamide, The metabolism of Repaglinide can be increased when combined with Ifosfamide.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Repaglinide.]
[N06AA02, imipramine, Imipramine may decrease the hypoglycemic activities of Repaglinide.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Repaglinide.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Repaglinide.]
[C03BA11, indapamide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Repaglinide.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Repaglinide.]
[N01BB08, articaine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Sitagliptin.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Vildagliptin.]
[C10AA06, cerivastatin, Cerivastatin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C07AA01, alprenolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Quinethazone.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Repaglinide.]
[N06AF05, iproniazid, Iproniazid may increase the hypoglycemic activities of Repaglinide.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypoglycemic activities of Repaglinide.]
[J04AC01, isoniazid, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Isoniazid.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Exenatide.]
[P02CF01, ivermectin, The excretion of Repaglinide can be decreased when combined with Ivermectin.]
[J01FA07, josamycin, The serum concentration of Repaglinide can be increased when it is combined with Josamycin.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Repaglinide.]
[L04AC07, tocilizumab, The metabolism of Repaglinide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Repaglinide.]
[J02AB02, ketoconazole, The serum concentration of Repaglinide can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Repaglinide can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The metabolism of Repaglinide can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The serum concentration of Repaglinide can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Repaglinide can be increased when combined with Abatacept.]
[S01GX08, ketotifen, The risk or severity of thrombocytopenia can be increased when Repaglinide is combined with Ketotifen.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Repaglinide.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Repaglinide can be increased when used in combination with Nalidixic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Labetalol.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Etacrynic acid.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Levonorgestrel.]
[C08EX01, lidoflazine, The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Repaglinide.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Repaglinide.]
[A07DA03, loperamide, The metabolism of Repaglinide can be decreased when combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Repaglinide can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The serum concentration of Repaglinide can be increased when it is combined with Temsirolimus.]
[V04CC02, magnesium sulfate, The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Repaglinide.]
[L01EA03, nilotinib, The metabolism of Repaglinide can be decreased when combined with Nilotinib.]
[C03BA05, mefruside, The therapeutic efficacy of Repaglinide can be increased when used in combination with Mefruside.]
[N03AB04, mephenytoin, The metabolism of Repaglinide can be decreased when combined with Mephenytoin.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Repaglinide.]
[N05AX13, paliperidone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Paliperidone.]
[H01CB03, lanreotide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lanreotide.]
[S01EC05, methazolamide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Methazolamide.]
[H03BB02, methimazole, The metabolism of Repaglinide can be decreased when combined with Methimazole.]
[N02BG08, ziconotide, The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Repaglinide.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Methotrimeprazine.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Methyclothiazide.]
[V04CG05, methylene blue, The metabolism of Repaglinide can be decreased when combined with Methylene blue.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Repaglinide.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Repaglinide.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Repaglinide.]
[C03BA08, metolazone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Repaglinide can be decreased when combined with Metronidazole.]
[S02AA13, miconazole, The metabolism of Repaglinide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Repaglinide.]
[G03XB01, mifepristone, The serum concentration of Repaglinide can be increased when it is combined with Mifepristone.]
[C09CA03, valsartan, The excretion of Repaglinide can be decreased when combined with Valsartan.]
[J01FA11, miocamycin, The serum concentration of Repaglinide can be increased when it is combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Repaglinide can be increased when combined with Mitotane.]
[C01BD01, amiodarone, The metabolism of Repaglinide can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the hypoglycemic activities of Repaglinide.]
[N02AA01, morphine, The metabolism of Repaglinide can be decreased when combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Repaglinide can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Repaglinide can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Repaglinide.]
[P01BA06, amodiaquine, The metabolism of Repaglinide can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Repaglinide can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Repaglinide.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Repaglinide.]
[C07AA12, nadolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Nadolol.]
[V03AB15, naloxone, The metabolism of Repaglinide can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Repaglinide can be increased when combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Repaglinide.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[N06AX21, duloxetine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Repaglinide.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Repaglinide can be increased when used in combination with Pipemidic acid.]
[N05AX14, iloperidone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Repaglinide.]
[C09CA07, telmisartan, Repaglinide may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[C10AD02, niacin, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypoglycemic activities of Repaglinide.]
[C08CA04, nicardipine, The metabolism of Repaglinide can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, Repaglinide may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Repaglinide.]
[C08CA07, nisoldipine, The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Repaglinide.]
[C08CA08, nitrendipine, Repaglinide may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[G03DC02, norethindrone, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[N06AA10, nortriptyline, Nortriptyline may decrease the hypoglycemic activities of Repaglinide.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Repaglinide.]
[G01AA01, nystatin, The excretion of Repaglinide can be decreased when combined with Nystatin.]
[H01CB02, octreotide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Ofloxacin.]
[J01FA05, oleandomycin, The serum concentration of Repaglinide can be increased when it is combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Repaglinide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Repaglinide can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Repaglinide.]
[G04CA02, tamsulosin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Tamsulosin.]
[C01AC01, ouabain, The excretion of Repaglinide can be decreased when combined with Ouabain.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Repaglinide.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Repaglinide can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Oxprenolol.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Repaglinide.]
[V04CH30, 4-aminohippuric acid, The excretion of Repaglinide can be decreased when combined with Aminohippuric acid.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Repaglinide.]
[N05AH05, asenapine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Asenapine.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Repaglinide.]
[C02KC01, pargyline, Pargyline may increase the hypoglycemic activities of Repaglinide.]
[J01MA03, pefloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Pefloxacin.]
[C07AA23, penbutolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Repaglinide.]
[N05CA01, pentobarbital, The metabolism of Repaglinide can be increased when combined with Pentobarbital.]
[C08EX02, perhexiline, The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Repaglinide.]
[N06AF03, phenelzine, Phenelzine may increase the hypoglycemic activities of Repaglinide.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Phenformin.]
[N03AA02, phenobarbital, The metabolism of Repaglinide can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Repaglinide.]
[A08AA01, phentermine, The therapeutic efficacy of Repaglinide can be increased when used in combination with Phentermine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Repaglinide.]
[L04AB06, golimumab, The metabolism of Repaglinide can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Repaglinide.]
[C07AA03, pindolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Pindolol.]
[C10AA05, atorvastatin, Repaglinide may decrease the excretion rate of Atorvastatin which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Repaglinide can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Pipotiazine.]
[S01BC06, piroxicam, The metabolism of Repaglinide can be decreased when combined with Piroxicam.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Repaglinide can be increased when used in combination with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Repaglinide can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Repaglinide can be decreased when combined with Irbesartan.]
[D05AX05, tazarotene, The metabolism of Repaglinide can be decreased when combined with Tazarotene.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Repaglinide.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Repaglinide.]
[L04AC08, canakinumab, The metabolism of Repaglinide can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Repaglinide can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Saxagliptin.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin lispro.]
[C10AA08, pitavastatin, Repaglinide may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Practolol.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Repaglinide.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Repaglinide.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Repaglinide.]
[P01BA03, primaquine, The metabolism of Repaglinide can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Repaglinide can be increased when combined with Primidone.]
[M04AB01, probenecid, The therapeutic efficacy of Repaglinide can be increased when used in combination with Probenecid.]
[S01HA05, procaine, Procaine may increase the hypoglycemic activities of Repaglinide.]
[L01XB01, procarbazine, Procarbazine may increase the hypoglycemic activities of Repaglinide.]
[C10AB05, fenofibrate, Repaglinide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C01BC03, propafenone, The therapeutic efficacy of Repaglinide can be increased when used in combination with Propafenone.]
[N01AX10, propofol, The metabolism of Repaglinide can be decreased when combined with Propofol.]
[C07AA05, propranolol, The therapeutic efficacy of Repaglinide can be increased when used in combination with Propranolol.]
[R03DC03, montelukast, The metabolism of Repaglinide can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Repaglinide.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Aripiprazole.]
[P01BD01, pyrimethamine, The metabolism of Repaglinide can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, Quinidine may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Quinine is combined with Repaglinide.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Repaglinide.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[J04AB02, rifampin, The serum concentration of Repaglinide can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The excretion of Repaglinide can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Repaglinide.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Repaglinide.]
[N05CA06, secobarbital, The metabolism of Repaglinide can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Repaglinide.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Repaglinide.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Repaglinide.]
[C03DA01, spironolactone, The metabolism of Repaglinide can be decreased when combined with Spironolactone.]
